Which has higher earnings & valuation, IMMP or SGMT?

Prima BioMed has higher revenue and earnings than Sagimet Biosciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Prima BioMed $4.08M 15.22 -$39.78M N/A N/A Sagimet Biosciences $2M 123.97 -$51.04M -$1.34 N/A

Is IMMP or SGMT more profitable?

Prima BioMed's return on equity of 0.00% beat Sagimet Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Prima BioMed N/A N/A N/A Sagimet Biosciences N/A -37.57% -35.52%

Does the media favor IMMP or SGMT?

In the previous week, Prima BioMed had 7 more articles in the media than Sagimet Biosciences. MarketBeat recorded 8 mentions for Prima BioMed and 1 mentions for Sagimet Biosciences. Prima BioMed's average media sentiment score of 0.00 equaled Sagimet Biosciences'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prima BioMed 0 Very Positive mention(s) 0 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Sagimet Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend CNTN or IMMP?

Prima BioMed has a consensus target price of $5.50, suggesting a potential upside of 1,205.17%. Given Prima BioMed's stronger consensus rating and higher possible upside, analysts plainly believe Prima BioMed is more favorable than Hillstream Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Hillstream Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Prima BioMed 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better earnings and valuation, CNTN or IMMP?

Hillstream Biopharma has higher earnings, but lower revenue than Prima BioMed. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Hillstream Biopharma N/A N/A -$35.92M -$1.15 N/A Prima BioMed $4.08M 15.22 -$39.78M N/A N/A

Is CNTN or IMMP more profitable?

Prima BioMed's return on equity of 0.00% beat Hillstream Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Hillstream Biopharma N/A -31.50% -24.72% Prima BioMed N/A N/A N/A

Does the media favor CNTN or IMMP?

In the previous week, Prima BioMed had 7 more articles in the media than Hillstream Biopharma. MarketBeat recorded 8 mentions for Prima BioMed and 1 mentions for Hillstream Biopharma. Hillstream Biopharma's average media sentiment score of 0.00 equaled Prima BioMed'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hillstream Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Prima BioMed 0 Very Positive mention(s) 0 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation & earnings, IMMP or QTTB?

Q32 Bio has higher revenue and earnings than Prima BioMed. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Prima BioMed $4.08M 15.22 -$39.78M N/A N/A Q32 Bio $53.74M 4.13 $29.82M $2.66 4.92

Is IMMP or QTTB more profitable?

Q32 Bio's return on equity of 149.23% beat Prima BioMed's return on equity. Company Net Margins Return on Equity Return on Assets Prima BioMed N/A N/A N/A Q32 Bio N/A 149.23% 34.50%

Which has better earnings and valuation, IMMP or KROS?

Keros Therapeutics has higher revenue and earnings than Prima BioMed. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Prima BioMed $4.08M 15.22 -$39.78M N/A N/A Keros Therapeutics $244.06M 0.91 $87.01M -$3.01 N/A

Does the media prefer IMMP or KROS?

In the previous week, Prima BioMed had 7 more articles in the media than Keros Therapeutics. MarketBeat recorded 8 mentions for Prima BioMed and 1 mentions for Keros Therapeutics. Prima BioMed's average media sentiment score of 0.00 equaled Keros Therapeutics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prima BioMed 0 Very Positive mention(s) 0 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Keros Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings and valuation, VYGR or IMMP?

Prima BioMed has lower revenue, but higher earnings than Voyager Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Voyager Therapeutics $36.49M 6.26 -$119.72M -$1.97 N/A Prima BioMed $4.08M 15.22 -$39.78M N/A N/A

Does the media refer more to VYGR or IMMP?

In the previous week, Prima BioMed had 4 more articles in the media than Voyager Therapeutics. MarketBeat recorded 8 mentions for Prima BioMed and 4 mentions for Voyager Therapeutics. Voyager Therapeutics' average media sentiment score of 0.45 beat Prima BioMed's score of 0.00 indicating that Voyager Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Voyager Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Prima BioMed 0 Very Positive mention(s) 0 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Prima BioMed (IMMP) Competitors

$0.42 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$0.42 0.00 (-0.33%)

As of 07/2/2026 07:45 PM Eastern

Compare

IMMP vs. SGMT, CNTN, QTTB, KROS, and VYGR

Should you buy Prima BioMed stock or one of its competitors? MarketBeat compares Prima BioMed with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Prima BioMed include Sagimet Biosciences (SGMT), Hillstream Biopharma (CNTN), Q32 Bio (QTTB), Keros Therapeutics (KROS), and Voyager Therapeutics (VYGR). These companies are all part of the "pharmaceutical products" industry.

How does Prima BioMed compare to Sagimet Biosciences?

Prima BioMed (NASDAQ:IMMP) and Sagimet Biosciences (NASDAQ:SGMT) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, risk, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends.

Prima BioMed has a beta of 2.23, indicating that its stock price is 123% more volatile than the broader market. Comparatively, Sagimet Biosciences has a beta of 3.35, indicating that its stock price is 235% more volatile than the broader market.

Prima BioMed has higher revenue and earnings than Sagimet Biosciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prima BioMed	$4.08M	15.22	-$39.78M	N/A	N/A
Sagimet Biosciences	$2M	123.97	-$51.04M	-$1.34	N/A

Prima BioMed's return on equity of 0.00% beat Sagimet Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prima BioMed	N/A	N/A	N/A
Sagimet Biosciences	N/A	-37.57%	-35.52%

Prima BioMed currently has a consensus target price of $5.50, suggesting a potential upside of 1,205.17%. Sagimet Biosciences has a consensus target price of $25.57, suggesting a potential upside of 236.02%. Given Prima BioMed's higher probable upside, research analysts plainly believe Prima BioMed is more favorable than Sagimet Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prima BioMed	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Sagimet Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

In the previous week, Prima BioMed had 7 more articles in the media than Sagimet Biosciences. MarketBeat recorded 8 mentions for Prima BioMed and 1 mentions for Sagimet Biosciences. Prima BioMed's average media sentiment score of 0.00 equaled Sagimet Biosciences'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prima BioMed	0 Very Positive mention(s)	0 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sagimet Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

2.3% of Prima BioMed shares are owned by institutional investors. Comparatively, 87.9% of Sagimet Biosciences shares are owned by institutional investors. 3.1% of Prima BioMed shares are owned by company insiders. Comparatively, 14.7% of Sagimet Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Prima BioMed and Sagimet Biosciences tied by winning 6 of the 12 factors compared between the two stocks.

How does Prima BioMed compare to Hillstream Biopharma?

Hillstream Biopharma (NASDAQ:CNTN) and Prima BioMed (NASDAQ:IMMP) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations, profitability and earnings.

In the previous week, Prima BioMed had 7 more articles in the media than Hillstream Biopharma. MarketBeat recorded 8 mentions for Prima BioMed and 1 mentions for Hillstream Biopharma. Hillstream Biopharma's average media sentiment score of 0.00 equaled Prima BioMed'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hillstream Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Prima BioMed	0 Very Positive mention(s)	0 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Hillstream Biopharma has higher earnings, but lower revenue than Prima BioMed.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hillstream Biopharma	N/A	N/A	-$35.92M	-$1.15	N/A
Prima BioMed	$4.08M	15.22	-$39.78M	N/A	N/A

Prima BioMed has a consensus target price of $5.50, suggesting a potential upside of 1,205.17%. Given Prima BioMed's stronger consensus rating and higher possible upside, analysts plainly believe Prima BioMed is more favorable than Hillstream Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hillstream Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Prima BioMed	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Prima BioMed's return on equity of 0.00% beat Hillstream Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hillstream Biopharma	N/A	-31.50%	-24.72%
Prima BioMed	N/A	N/A	N/A

1.2% of Hillstream Biopharma shares are held by institutional investors. Comparatively, 2.3% of Prima BioMed shares are held by institutional investors. 3.3% of Hillstream Biopharma shares are held by company insiders. Comparatively, 3.1% of Prima BioMed shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Hillstream Biopharma has a beta of 1.42, meaning that its stock price is 42% more volatile than the broader market. Comparatively, Prima BioMed has a beta of 2.23, meaning that its stock price is 123% more volatile than the broader market.

Summary

Prima BioMed beats Hillstream Biopharma on 9 of the 11 factors compared between the two stocks.

How does Prima BioMed compare to Q32 Bio?

Prima BioMed (NASDAQ:IMMP) and Q32 Bio (NASDAQ:QTTB) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, profitability, analyst recommendations, risk, valuation and dividends.

2.3% of Prima BioMed shares are owned by institutional investors. Comparatively, 31.3% of Q32 Bio shares are owned by institutional investors. 3.1% of Prima BioMed shares are owned by insiders. Comparatively, 34.5% of Q32 Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Prima BioMed had 8 more articles in the media than Q32 Bio. MarketBeat recorded 8 mentions for Prima BioMed and 0 mentions for Q32 Bio. Prima BioMed's average media sentiment score of 0.00 equaled Q32 Bio'saverage media sentiment score.

Company	Overall Sentiment
Prima BioMed	Neutral
Q32 Bio	Neutral

Q32 Bio has higher revenue and earnings than Prima BioMed.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prima BioMed	$4.08M	15.22	-$39.78M	N/A	N/A
Q32 Bio	$53.74M	4.13	$29.82M	$2.66	4.92

Q32 Bio's return on equity of 149.23% beat Prima BioMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prima BioMed	N/A	N/A	N/A
Q32 Bio	N/A	149.23%	34.50%

Prima BioMed has a beta of 2.23, indicating that its share price is 123% more volatile than the broader market. Comparatively, Q32 Bio has a beta of 0.24, indicating that its share price is 76% less volatile than the broader market.

Prima BioMed presently has a consensus price target of $5.50, indicating a potential upside of 1,205.17%. Q32 Bio has a consensus price target of $13.50, indicating a potential upside of 3.13%. Given Prima BioMed's higher possible upside, equities analysts clearly believe Prima BioMed is more favorable than Q32 Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prima BioMed	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Q32 Bio	0 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.60

Summary

Q32 Bio beats Prima BioMed on 8 of the 12 factors compared between the two stocks.

How does Prima BioMed compare to Keros Therapeutics?

Prima BioMed (NASDAQ:IMMP) and Keros Therapeutics (NASDAQ:KROS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, dividends, media sentiment and valuation.

Keros Therapeutics has higher revenue and earnings than Prima BioMed.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prima BioMed	$4.08M	15.22	-$39.78M	N/A	N/A
Keros Therapeutics	$244.06M	0.91	$87.01M	-$3.01	N/A

Prima BioMed currently has a consensus target price of $5.50, indicating a potential upside of 1,205.17%. Keros Therapeutics has a consensus target price of $20.40, indicating a potential upside of 81.17%. Given Prima BioMed's higher probable upside, equities research analysts clearly believe Prima BioMed is more favorable than Keros Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prima BioMed	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Keros Therapeutics	1 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25

Prima BioMed has a net margin of 0.00% compared to Keros Therapeutics' net margin of -256.60%. Prima BioMed's return on equity of 0.00% beat Keros Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prima BioMed	N/A	N/A	N/A
Keros Therapeutics	-256.60%	-17.04%	-15.84%

In the previous week, Prima BioMed had 7 more articles in the media than Keros Therapeutics. MarketBeat recorded 8 mentions for Prima BioMed and 1 mentions for Keros Therapeutics. Prima BioMed's average media sentiment score of 0.00 equaled Keros Therapeutics'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prima BioMed	0 Very Positive mention(s)	0 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Keros Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Prima BioMed has a beta of 2.23, indicating that its stock price is 123% more volatile than the broader market. Comparatively, Keros Therapeutics has a beta of 0.97, indicating that its stock price is 3% less volatile than the broader market.

2.3% of Prima BioMed shares are owned by institutional investors. Comparatively, 71.6% of Keros Therapeutics shares are owned by institutional investors. 3.1% of Prima BioMed shares are owned by company insiders. Comparatively, 20.6% of Keros Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Prima BioMed beats Keros Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Prima BioMed compare to Voyager Therapeutics?

Voyager Therapeutics (NASDAQ:VYGR) and Prima BioMed (NASDAQ:IMMP) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, risk, media sentiment, valuation, dividends and profitability.

In the previous week, Prima BioMed had 4 more articles in the media than Voyager Therapeutics. MarketBeat recorded 8 mentions for Prima BioMed and 4 mentions for Voyager Therapeutics. Voyager Therapeutics' average media sentiment score of 0.45 beat Prima BioMed's score of 0.00 indicating that Voyager Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Voyager Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Prima BioMed	0 Very Positive mention(s)	0 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Voyager Therapeutics currently has a consensus price target of $16.50, suggesting a potential upside of 336.51%. Prima BioMed has a consensus price target of $5.50, suggesting a potential upside of 1,205.17%. Given Prima BioMed's higher probable upside, analysts clearly believe Prima BioMed is more favorable than Voyager Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Voyager Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Prima BioMed	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

48.0% of Voyager Therapeutics shares are held by institutional investors. Comparatively, 2.3% of Prima BioMed shares are held by institutional investors. 12.7% of Voyager Therapeutics shares are held by company insiders. Comparatively, 3.1% of Prima BioMed shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Voyager Therapeutics has a beta of 1.27, suggesting that its stock price is 27% more volatile than the broader market. Comparatively, Prima BioMed has a beta of 2.23, suggesting that its stock price is 123% more volatile than the broader market.

Prima BioMed has a net margin of 0.00% compared to Voyager Therapeutics' net margin of -319.61%. Prima BioMed's return on equity of 0.00% beat Voyager Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Voyager Therapeutics	-319.61%	-55.97%	-43.12%
Prima BioMed	N/A	N/A	N/A

Prima BioMed has lower revenue, but higher earnings than Voyager Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Voyager Therapeutics	$36.49M	6.26	-$119.72M	-$1.97	N/A
Prima BioMed	$4.08M	15.22	-$39.78M	N/A	N/A

Summary

Prima BioMed beats Voyager Therapeutics on 8 of the 15 factors compared between the two stocks.

Get Prima BioMed News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMMP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IMMP vs. The Competition

Export

Metric	Prima BioMed	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$62.10M	$3.78B	$7.16B	$12.48B
Dividend Yield	N/A	2.16%	2.66%	6.52%
P/E Ratio	N/A	21.61	28.02	24.70
Price / Sales	15.22	340.19	540.37	99.46
Price / Cash	N/A	147.12	49.26	57.09
Price / Book	0.67	8.66	10.96	6.46
Net Income	-$39.78M	$23.81M	$3.57B	$337.01M
7 Day Performance	6.95%	3.39%	2.12%	1.69%
1 Month Performance	11.90%	10.81%	5.25%	3.81%
1 Year Performance	-75.36%	62.61%	33.29%	23.90%

Prima BioMed Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IMMP Prima BioMed	1.4316 of 5 stars	$0.42 flat	$5.50 +1,205.2%	-75.4%	$62.10M	$4.08M	N/A	2,021	Gap Up
SGMT Sagimet Biosciences	2.5199 of 5 stars	$7.79 +10.3%	$25.57 +228.3%	-6.6%	$230.05M	$2M	N/A	8
CNTN Hillstream Biopharma	0.1522 of 5 stars	$2.78 -6.4%	N/A	N/A	$229.05M	N/A	N/A	2	Analyst Upgrade Gap Up
QTTB Q32 Bio	2.8282 of 5 stars	$14.14 +7.4%	$13.50 -4.5%	+809.0%	$223.31M	$53.74M	5.32	39	Positive News
KROS Keros Therapeutics	2.7087 of 5 stars	$10.93 -0.5%	$20.40 +86.6%	-15.5%	$217.51M	$244.06M	N/A	100	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IMMP) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Prima BioMed (IMMP) Competitors

IMMP vs. SGMT, CNTN, QTTB, KROS, and VYGR

How does Prima BioMed compare to Sagimet Biosciences?

Summary

How does Prima BioMed compare to Hillstream Biopharma?

Summary

How does Prima BioMed compare to Q32 Bio?

Summary

How does Prima BioMed compare to Keros Therapeutics?

Summary

How does Prima BioMed compare to Voyager Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMMP vs. The Competition

Prima BioMed Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Prima BioMed (IMMP) Competitors

IMMP vs. SGMT, CNTN, QTTB, KROS, and VYGR

How does Prima BioMed compare to Sagimet Biosciences?

Which has more risk and volatility, IMMP or SGMT?

Which has higher earnings & valuation, IMMP or SGMT?

Is IMMP or SGMT more profitable?

Do analysts recommend IMMP or SGMT?

Does the media favor IMMP or SGMT?

Do insiders & institutionals believe in IMMP or SGMT?

Summary

How does Prima BioMed compare to Hillstream Biopharma?

Does the media favor CNTN or IMMP?

Which has better earnings and valuation, CNTN or IMMP?

Do analysts recommend CNTN or IMMP?

Is CNTN or IMMP more profitable?

Do insiders & institutionals believe in CNTN or IMMP?

Which has more risk & volatility, CNTN or IMMP?

Summary

How does Prima BioMed compare to Q32 Bio?

Do institutionals and insiders believe in IMMP or QTTB?

Does the media prefer IMMP or QTTB?

Which has preferable valuation & earnings, IMMP or QTTB?

Is IMMP or QTTB more profitable?

Which has more risk & volatility, IMMP or QTTB?

Do analysts prefer IMMP or QTTB?

Summary

How does Prima BioMed compare to Keros Therapeutics?

Which has better earnings and valuation, IMMP or KROS?

Do analysts rate IMMP or KROS?

Is IMMP or KROS more profitable?

Does the media prefer IMMP or KROS?

Which has more risk and volatility, IMMP or KROS?

Do institutionals & insiders believe in IMMP or KROS?

Summary

How does Prima BioMed compare to Voyager Therapeutics?

Does the media refer more to VYGR or IMMP?

Do analysts rate VYGR or IMMP?

Do insiders & institutionals believe in VYGR or IMMP?

Which has more volatility and risk, VYGR or IMMP?

Is VYGR or IMMP more profitable?

Which has stronger earnings and valuation, VYGR or IMMP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMMP vs. The Competition

Prima BioMed Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools